JY
STOK icon

Jeff Yass’s Stoke Therapeutics STOK Stock Holding History

Jeff Yass’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687K Sell
21,000
-13,700
-39% -$440K ﹤0.01% 9153
2026
Q1 		$1.13M Buy
34,700
+8,500
+32% +$279K ﹤0.01% 7560
2025
Q4 		$832K Sell
26,200
-14,300
-35% -$430K ﹤0.01% 7590
2025
Q3 		$952K Sell
40,500
-16,300
-29% -$279K ﹤0.01% 7476
2025
Q2 		$645K Sell
56,800
-50,400
-47% -$479K ﹤0.01% 8578
2025
Q1 		$713K Buy
107,200
+92,300
+619% +$861K ﹤0.01% 8100
2024
Q4 		$164K Buy
14,900
+3,000
+25% +$36.9K ﹤0.01% 10943
2024
Q3 		$146K Buy
+11,900
New +$169K ﹤0.01% 10767
2024
Q2 		– Sell
-10,100
Closed -$136K – 13196
2024
Q1 		$136K Buy
+10,100
New +$61.2K ﹤0.01% 10982
2021
Q4 		– Sell
-29,300
Closed -$745K – 13878
2021
Q3 		$745K Buy
+29,300
New +$817K ﹤0.01% 8338
2021
Q1 		– Sell
-3,800
Closed -$235K – 12825
2020
Q4 		$235K Buy
+3,800
New +$174K ﹤0.01% 9775

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's STOK Position: Q2 2026 in Review

Jeff Yass sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 57,291 shares — an estimated $1.84M sold.

Jeff Yass first reported a position in STOK in Q1 2020 and held it in 21 quarters. The position peaked at $2.07M in Q4 2024. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Jeff Yass reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 57,291 Stoke Therapeutics shares in Q2 2026, an estimated $1.84M.
  • Jeff Yass first reported a position in Stoke Therapeutics in Q1 2020 and held it in 21 quarters.
  • Jeff Yass's Stoke Therapeutics position peaked at $2.07M in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.